Literature DB >> 19901621

Effect of reverse transcriptase inhibitors and mutations on the low-cost Cavidi reverse transcriptase viral load assay.

Lisette B van Rooijen, Vicki Greengrass, Lisa M Morris, Megan M Plate, Maelenn Gouillou, Gilda Tachedjian, Nicolas Sluis-Cremer, Anna C Hearps, Suzanne M Crowe.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19901621     DOI： 10.1097/QAI.0b013e3181b9e726

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  3 in total

1.  Performance characteristics of the Cavidi ExaVir viral load assay and the ultra-sensitive P24 assay relative to the Roche Monitor HIV-1 RNA assay.

Authors:  Paul Stewart; Ada Cachafeiro; Sonia Napravnik; Joseph J Eron; Ian Frank; Charles van der Horst; Ronald J Bosch; Daniel Bettendorf; Peter Bohlin; Susan A Fiscus
Journal:  J Clin Virol       Date:  2010-09-15       Impact factor: 3.168

2.  Assessment of the Cavidi ExaVir Load Assay for Monitoring Plasma Viral Load in HIV-2-Infected Patients.

Authors:  Pedro Borrego; Maria Fátima Gonçalves; Perpétua Gomes; Lavínia Araújo; Inês Moranguinho; Inês Brito Figueiredo; Isabel Barahona; José Rocha; Claudino Mendonça; Maria Cesarina Cruz; Jorge Barreto; Nuno Taveira
Journal:  J Clin Microbiol       Date:  2017-05-17       Impact factor: 5.948

3.  Can HIV reverse transcriptase activity assay be a low-cost alternative for viral load monitoring in resource-limited settings?

Authors:  Soham Gupta; Riya Palchaudhuri; Ujjwal Neogi; Hiresave Srinivasa; Per Ashorn; Ayesha De Costa; Clas Källander; Anita Shet
Journal:  BMJ Open       Date:  2016-01-27       Impact factor: 2.692
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.